Report
Hyloris Pharma - Shares suspended pending 2023 audit and forensic review of Qliniq transaction
KPMG informed the Audit committee that additional work is required to finalize the 2023 audit. They initiated a forensic independent review regarding the Qliniq transaction, including internal communication and documentation practices. Pending the review, shares will remain suspended.The Company does not expect to change the restated accounting treatment related to the Qliniq transactions.TP and BUY rating reiterated as we believe the current share price is not fully reflective of the pipeline potential. We expect the share price to be fueled by a mixture of pipeline, clinical, & commercial achievements in 2024
Underlying
Hyloris Pharmaceuticals
Provider
Degroof Petercam
We are an investment house with Belgian roots founded on more than 150 years of trust.
As a private company owned by long-term committed shareholders, we are independent. Naturally and structurally. Our experts have the knowledge to think and act without bias, and to make decisions that benefit our clients. Today and tomorrow.
Laura Roba
Other Reports on these Companies
Other Reports from Degroof Petercam
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.